Tumor Response Rate

← Back to Glossary

Definition

Tumor response rate is the percentage of patients whose cancer shrinks or disappears during treatment, measured according to standardized criteria. It is a surrogate endpoint used in cancer trials to assess whether a treatment affects tumor size without waiting years to measure survival.

Correct Scientific Usage

Researchers define response using objective criteria such as RECIST (Response Evaluation Criteria in Solid Tumors). Complete response means all detectable cancer disappears; partial response means tumors shrink by at least 30%. Response rate indicates whether treatment affects tumor biology but doesn't necessarily predict whether patients live longer or feel better.

Scientists distinguish response rate from more meaningful endpoints like overall survival and progression-free survival. High response rates are promising but require validation with longer-term outcomes, as tumors can shrink without extending life if disease progresses elsewhere or treatment loses effectiveness.

Common Misunderstandings

Tumor response rate is often equated with treatment success when it's a biological measure, not a clinical outcome. A drug causing many tumors to shrink (high response rate) may not help patients live longer if the response is temporary, cancer progresses in other ways, or treatment toxicity causes harm.

People assume tumor shrinkage means cure, when most responses are temporary and cancer eventually progresses. There's also confusion between response rate (percentage of patients responding) and depth of response (how much tumors shrink), which measure different aspects of treatment effect.

Why It Matters

Understanding tumor response rate prevents confusing biological activity with clinical benefit. It explains why drugs showing impressive response rates may not gain approval if they don't extend survival or improve quality of life. This distinction is crucial for evaluating cancer treatment claims. "Shrinks tumors" sounds compelling but doesn't guarantee patients benefit unless response translates to longer or better lives.

References

  • Tumor Response Assessment for Precision Cancer Therapy, ASCO
  • New response evaluation criteria in solid tumours: Revised RECIST guideline, European Journal of Cancer

← Back to Glossary